非霍奇金淋巴瘤患者接受CD19嵌合抗原受体T细胞治疗后侵袭性真菌病发生率低
该单中心回顾性研究纳入2017年12月至2021年9月接受CD19 CAR T细胞治疗的非霍奇金淋巴瘤成人患者280例,患者未接受常规抗酵母或抗霉菌预防。8例(2.9%)发生侵袭性真菌病,100天累积发生率为1.8%(95%CI 0.8%-4.4%)。尽管毒性常见,侵袭性真菌病罕见,结果提示在机构侵袭性真菌病发生率低的背景下,常规抗真菌预防可能无指征。
要点
- 280例接受CD19 CAR T细胞治疗的非霍奇金淋巴瘤患者中,8例(2.9%)发生侵袭性真菌病。
- 100天侵袭性真菌病累积发生率为1.8%(95%CI 0.8%-4.4%)。
- 作者认为在侵袭性真菌病机构发生率低的背景下,常规抗真菌预防可能无指征。
核心结论
- 在接受CD19 CAR T细胞治疗的非霍奇金淋巴瘤患者中,尽管毒性常见,未常规抗真菌预防时侵袭性真菌病罕见。
- 作者认为,在侵袭性真菌病机构发生率低的背景下,常规抗真菌预防可能无指征。
研究设计与样本
- 单中心回顾性研究,纳入2017年12月至2021年9月接受CD19 CAR T细胞治疗的非霍奇金淋巴瘤成人患者280例。
- 患者未接受常规抗酵母或抗霉菌预防。
- 侵袭性真菌病识别时间为细胞输注日至末次随访。
- 采用竞争风险模型计算100天和18个月累积发生率函数,竞争风险包括无侵袭性真菌病死亡、开始挽救治疗和造血细胞移植。
主要发现
- 8例患者(2.9%)发生侵袭性真菌病,包括3例耶氏肺孢子菌肺炎、3例侵袭性霉菌感染和2例侵袭性酵母菌感染。
- 考虑竞争风险后,100天侵袭性真菌病累积发生率为1.8%(95%CI 0.8%-4.4%)。
- 280例患者中,早期毒性包括细胞因子释放综合征(85%)和免疫效应细胞相关神经毒性综合征(55%),第30天后晚期毒性包括3级和4级中性粒细胞减少(41%)和低CD4 T细胞计数(20%)常见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, although its use may be complicated by toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections. Invasive fungal disease (IFD) has been reported after CAR T-cell therapy, but the incidence in the absence of antifungal prophylaxis is unknown. Optimal prophylaxis strategies are widely debated. We performed a single-center retrospective study of 280 adults receiving CD19 CAR T-cell therapy for non-Hodgkin lymphoma (NHL) from December 2017 through September 2021. Patients did not receive routine antiyeast or antimold prophylaxis. IFD was identified between day of cell infusion and last follow-up. Cumulative incidence functions were calculated at 100 days and 18 months based on time to IFD, using dates of IFD-free death, initiation of salvage treatment, and hematopoietic cell transplantation as competing risks. Eight patients (2.9%) developed IFD, including 3 Pneumocystis jirovecii pneumonia, 3 invasive mold infections (IMIs), and 2 invasive yeast infections (IYIs). The 100-day cumulative incidence of IFD accounting for competing risks was 1.8% (95% confidence interval [CI], 0.8% to 4.4%). Among the 280 patients, early toxicities including CRS (85%) and ICANS (55%) and late toxicities after day 30 including grades 3 and 4 neutropenia (41%) and low CD4 T-cell count (20%) were common. IFD was rare among patients who received CD19 CAR T-cell therapy for NHL in the absence of routine antifungal prophylaxis, despite frequent toxicities. These results suggest that, in settings with low institutional rates of IFD, routine antifungal prophylaxis may not be indicated.
引用
- Little JS, Aleissa MM, Beluch K, et al. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Adv. 2022. PMID: 35802461. doi:10.1182/bloodadvances.2022007474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。